B.07 Review of patients with Spinal Muscular Atrophy treated with Nusinersen in Ontario

• Published in: Canadian journal of neurological sciences 2018-06, Vol.45 (s2), p.S13-S13
• Main Authors: Remtulla, S, Zapata-Aldana, E, Gonorazky, H, Boyd, J, Scholtes, C, Hicks, R, Leung, A, Dowling, J, Vajsar, J, McMillan, H, Tarnopolsky, M, Campbell, C
• Format: Article
• Language: English
• Subjects: CSCN / CACN CHAIR’S SELECT ABSTRACTS; Neuromuscular diseases; PLATFORM PRESENTATIONS
• ISSN: 0317-1671; 2057-0155
• DOI: 10.1017/cjn.2018.95

Background: Spinal Muscular Atrophy (SMA) is an autosomal recessive neurodegenerative disease. In June 2017, Health Canada approved Nusinersen, currently the only available drug for SMA. Since 2016, patients in Ontario have been treated clinically with Nusinersen through different access programs. Methods: Retrospective case series of patients with SMA treated clinically with Nusinersen in Ontario, describing clinical characteristics and logistics of intrathecal Nusinersen administration. Results: Twenty patients have been treated across four centres. To date, we have reviewed 8 cases at one centre (seven SMA Type I, one SMA Type II). Age at first dose ranged from 3-156 months and disease duration 9-166 months. Patients had received 4-7 doses at last evaluation. Three patients with scoliosis (2 with spinal rods) required fluoroscopy-guided radiologist administration, and 4 required general anesthesia. No complications/adverse events were reported. At last follow up, 5/8 families reported improved daily activities. Of 5 patients with baseline and follow up motor function testing, 3 demonstrated improved scores. One patient died due to respiratory decline at age 9 months, despite improved motor outcome scores. Conclusions: We describe the first Canadian post-marketing experience with Nusinersen. Timely dissemination of this information is needed to guide clinicians, hospital administrators, and policy-makers.